A platform company
Linking pharmaceutical innovation and
commercialization with strong product
lifecycle management capability
commercialization with strong product
lifecycle management capability
Focusing on unmet clinical needs, we collaborate with global biotech/biopharma to jointly develop first- or best-in-class innovative products.
Adhering to the patient-centered philosophy, we are dedicated to providing competitive products and services that enable the more effective diagnosis and treatment, whilst enhancing clinical practice to the ultimate benefit of the patient.
On 25 June 2025, China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group”) received an eligibility-to-list letter (“ETL”) from the Singapore Exchange Securities Trading Limited (the “SGX-ST”) in respect of the Proposed Secondary Listing and, subject to fulfilment of the conditions set out therein, the Shares are expected to be listed and to commence trading on the SGX-ST on around 15 July 2025. The ETL is not an indication of the merits of the Proposed Secondary Listing, the Group and/or the Shares. The Proposed Secondary Listing will not involve issuance of new Shares, and the Shares will continue to be listed and traded on the Hong Kong Stock Exchange thereafter. The Directors believe that upon completion of the Proposed Secondary Listing on the SGX-ST, the Group will be able to attract funds focusing on Asia-Pacific investments and local capital in Southeast Asia, thereby optimizing the shareholder structure. At the same time, it will also have a more […]
We collaborate with global innovative companies in flexible structures to jointly build a pharmaceutical ecosystem in a sustainable and collaborative setting for the benefit of all stakeholders.
If you are interested in joining us, or curious about our business and products, please feel free to contact us.